Caitong International Asset Management Co. Ltd Acquires 602 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Caitong International Asset Management Co. Ltd significantly increased its stake in Alnylam Pharmaceuticals by 3,762.5% during the first quarter, now owning 618 shares valued at approximately $167,000.
• Alnylam Pharmaceuticals reported a quarterly earnings per share (EPS) of $0.32, surpassing analysts' expectations of a loss, and saw a revenue increase of 17.3% compared to the previous year.
• Several prominent institutional investors have also boosted their positions in Alnylam, indicating a strong confidence in the biotech company's growth potential.

Caitong International Asset Management Co. Ltd raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 3,762.5% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 618 shares of the biopharmaceutical company's stock after acquiring an additional 602 shares during the period. Caitong International Asset Management Co. Ltd's holdings in Alnylam Pharmaceuticals were worth $167,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of ALNY. Capital World Investors increased its holdings in shares of Alnylam Pharmaceuticals by 0.6% during the 4th quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock worth $3,906,284,000 after buying an additional 92,101 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company's stock worth $3,525,544,000 after buying an additional 323,206 shares during the last quarter. Capital Research Global Investors increased its holdings in shares of Alnylam Pharmaceuticals by 32.9% during the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock worth $1,639,767,000 after buying an additional 1,724,610 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its position in Alnylam Pharmaceuticals by 39.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock worth $1,031,705,000 after purchasing an additional 1,245,195 shares during the period. Finally, Northern Trust Corp boosted its position in Alnylam Pharmaceuticals by 19.6% during the 4th quarter. Northern Trust Corp now owns 878,860 shares of the biopharmaceutical company's stock worth $206,805,000 after purchasing an additional 143,941 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock traded up $7.96 during trading on Monday, hitting $456.87. 1,399,226 shares of the company's stock traded hands, compared to its average volume of 954,176. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The firm's fifty day moving average price is $345.09 and its 200 day moving average price is $290.51. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $457.92. The company has a market cap of $59.89 billion, a PE ratio of -184.97 and a beta of 0.25.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm had revenue of $773,689 billion during the quarter, compared to the consensus estimate of $633.54 million. During the same period last year, the firm posted ($0.13) EPS. The firm's quarterly revenue was up 17.3% on a year-over-year basis. Analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ALNY. Jefferies Financial Group upped their price target on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a "buy" rating in a research report on Monday, July 7th. Piper Sandler upped their price target on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an "overweight" rating in a research report on Friday, August 1st. Truist Financial began coverage on shares of Alnylam Pharmaceuticals in a research report on Monday, July 21st. They set a "buy" rating and a $385.00 price target for the company. UBS Group upped their price target on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Finally, JPMorgan Chase & Co. upped their price objective on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an "overweight" rating in a research report on Wednesday, August 6th. Four investment analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $405.33.

Insider Buying and Selling

In related news, CEO Yvonne Greenstreet sold 19,297 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the completion of the transaction, the chief executive officer owned 48,948 shares in the company, valued at approximately $14,978,088. The trade was a 28.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Dennis A. Ausiello sold 31,448 shares of the business's stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the transaction, the director owned 911 shares of the company's stock, valued at approximately $397,724.38. This represents a 97.18% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 82,385 shares of company stock valued at $29,265,349. 1.20% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.